UBS Asset Management Americas Inc. increased its position in Becton Dickinson and Co. (NYSE:BDX) by 8.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 756,535 shares of the company’s stock after buying an additional 60,203 shares during the period. UBS Asset Management Americas Inc. owned about 0.36% of Becton Dickinson and worth $135,972,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in shares of Becton Dickinson and by 0.5% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 31,473 shares of the company’s stock worth $5,338,000 after buying an additional 150 shares during the period. Quotient Investors LLC boosted its stake in shares of Becton Dickinson and by 99.9% in the second quarter. Quotient Investors LLC now owns 7,583 shares of the company’s stock worth $1,286,000 after buying an additional 3,790 shares during the period. Gulf International Bank UK Ltd boosted its stake in shares of Becton Dickinson and by 4.8% in the second quarter. Gulf International Bank UK Ltd now owns 65,007 shares of the company’s stock worth $11,024,000 after buying an additional 3,000 shares during the period. Central Bank & Trust Co. boosted its stake in shares of Becton Dickinson and by 7.9% in the second quarter. Central Bank & Trust Co. now owns 9,049 shares of the company’s stock worth $1,535,000 after buying an additional 662 shares during the period. Finally, Bank of Stockton boosted its stake in shares of Becton Dickinson and by 6.3% in the second quarter. Bank of Stockton now owns 5,944 shares of the company’s stock worth $1,008,000 after buying an additional 350 shares during the period. 81.35% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Becton Dickinson and Co. (NYSE:BDX) opened at 172.73 on Wednesday. The company has a 50 day moving average of $171.40 and a 200 day moving average of $172.45. Becton Dickinson and Co. has a 52 week low of $129.50 and a 52 week high of $181.76. The company has a market capitalization of $36.67 billion, a price-to-earnings ratio of 38.47 and a beta of 1.04.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, November 3rd. The company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.09 by $0.03. Becton Dickinson and had a net margin of 7.82% and a return on equity of 24.45%. The firm earned $3.23 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same period last year, the firm posted $1.94 earnings per share. Becton Dickinson and’s revenue for the quarter was up 5.6% compared to the same quarter last year. On average, equities analysts forecast that Becton Dickinson and Co. will post $9.52 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 30th. Shareholders of record on Friday, December 9th will be paid a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.69%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.66. The ex-dividend date is Wednesday, December 7th. Becton Dickinson and’s payout ratio is presently 58.54%.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/30/ubs-asset-management-americas-inc-increases-stake-in-becton-dickinson-and-co-bdx.html.

BDX has been the subject of a number of recent analyst reports. Leerink Swann reiterated a “hold” rating on shares of Becton Dickinson and in a report on Tuesday, August 9th. Zacks Investment Research lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Wednesday, November 16th. Cowen and Company reiterated an “outperform” rating and set a $185.00 price target on shares of Becton Dickinson and in a report on Tuesday, August 16th. Citigroup Inc. lowered shares of Becton Dickinson and from a “neutral” rating to a “sell” rating and lowered their price target for the company from $167.00 to $165.00 in a report on Friday, September 23rd. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $189.00 price target (down from $197.00) on shares of Becton Dickinson and in a report on Friday, November 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $175.65.

In other Becton Dickinson and news, insider Stephen Sichak sold 10,352 shares of Becton Dickinson and stock in a transaction on Friday, November 4th. The shares were sold at an average price of $176.10, for a total transaction of $1,822,987.20. Following the completion of the transaction, the insider now directly owns 26,892 shares of the company’s stock, valued at $4,735,681.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Linda M. Tharby sold 11,704 shares of Becton Dickinson and stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $177.27, for a total transaction of $2,074,768.08. Following the transaction, the insider now directly owns 22,146 shares of the company’s stock, valued at $3,925,821.42. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

5 Day Chart for NYSE:BDX

Receive News & Stock Ratings for Becton Dickinson and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co. and related stocks with our FREE daily email newsletter.